Ilan Danieli has served as Precipio's CEO since founding the company in 2011. With over 20 years managing small and medium-size companies, some of his previous experiences include COO of Osiris, a publicly-traded company based in New York City with operations in the US, Canada, Europe; and VP of Operation at Laurus Capital Management, a multi-billion dollar hedge fund; as well as in various other entrepreneurial ventures. Ilan holds an MBA from the Darden School at the University of Virginia, and a BA in Economics from Bar-Ilan University in Israel, and served in the Israeli military as a tank commander. He is also a private pilot, and while on the ground, he enjoys travel, scuba diving, skiing (snow and water), and also dabbles in gourmet cooking.
Mr. Iberger currently serves as the Chief Financial Officer of Precipio Diagnostics, joining Precipio in October 2016. For the years 1990 through 2015, Mr. Iberger held the positions of Chief Financial Officer and Executive Vice President at Dianon Systems, DigiTrace Care Services and SleepMed Inc. Mr. Iberger has significant diagnostic healthcare experience in mergers and acquisitions private equity transactions, public offerings and executive management in high growth environments. Mr. Iberger holds a Master's Degree in Finance from Hofstra University and a Bachelor of Science Degree in Accounting from the University of Connecticut.
Mr. Miller has over 20 years experience in the diagnostic and biotechnology sectors, with in-depth experience in developing and implementing business strategies. Prior to joining Precipio, Mr. Miller served as SVP & General Manager Patient Testing for Transgenomic. Mr. Miller held the positions of Chief Commercial Officer at BG Medicine where he led the early commercialization of that company’s cardiac diagnostic assay Galectin-3 and President and Chief Commercial Officer at Mira Dx. He also held a variety of key positions within Athena Diagnostics with responsibilities for reimbursement, corporate accounts, business development, marketing and sales. His last position with Athena was as the Vice President of Sales & Marketing as that company grew from $6 million to over $100 million in sales. Mr. Miller received a BA in Business Psychology from Miami University.
A. Zaki Sabet has been with Precipio since co-founding the company in 2011 and currently serves as the Chief Operating Officer. He holds over 12 years of experience in laboratory management spanning all fields of reference laboratory operations primarily focusing on cancer diagnostics. Prior to Precipio, Zaki has served as a consultant with the College of American Pathologists (CAP) for many years as well as several diagnostic companies in setting up their specialized cancer testing operations. Zaki holds a Bachelor of Science degree in Biomedical Engineering from the New Jersey Institute of Technology.
Ori Karev is a senior executive with global entrepreneur and intraprenuer experience. As an executive of leading multinational organizations, Ori served as CEO of UnitedHealthCare’s International division (global healthcare insurance and clinical networks operation in several countries), growing it from a relatively small business to having a presence in 100 countries with operations in China, India, England, Netherlands, Canada and the US. Ori also lead the division’s M&A of several business units in Malaysia, Philippines, Portugal, Canada, the UK and the US. Finally, Ori managed UHGI’s introduction of reinsurance activities with Japanese and Korean insurers. Ori spent the last decade leading, promoting and investing in several Healthtech ventures such as MedAware, ContinUse, HelpAround, VideoTherapy, and eWaveMD, as well as several Insurance companies such as MedSave India, MedSurance (as Founder & CEO), and Leumit Health Fund (Regional CEO). As an attorney (NY and CT Bars), Ori spent five years practicing law with Ernst & Young and a small M&A boutique firm. Ori holds a JD (Cardozo School of Law), an MBA (University of Hartford) and a BA (Tel-Aviv University) degrees, and has completed an executive program at Harvard Business School.
Dr. Mohamed is one of the co-founders of Precipio, Inc. (NASDAQ: PRPO), and currently serves as Precipio’s VP of R&D, as well as the laboratory’s Technical Director. In this dual role, Ayman is responsible for the entire process from conceptualization and invention of proprietary technologies, through design and development, economic cost analysis and modeling, testing and validation; and finally, the technical implementation of the technologies for clinical use in Precipio’s laboratories. Ayman has been responsible for the development and introduction of ground-breaking products such as IV-Cell™, HemeScreen™, and ICE-COLD PCR™. Prior to Precipio, Ayman served in various technical and research positions in both commercial diagnostic companies as well as academic centers such as Yale University. Ayman is also a certified CAP inspector. He holds an MD and a Masters in Human Genetics.